Alvotech (ALVO)
NASDAQ: ALVO · IEX Real-Time Price · USD
13.88
+0.11 (0.80%)
At close: May 31, 2024, 4:00 PM
14.09
+0.21 (1.51%)
After-hours: May 31, 2024, 5:27 PM EDT
Alvotech Revenue
Alvotech had revenue of $114.39M in the twelve months ending March 31, 2024, with 14.27% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $36.89M with 132.29% year-over-year growth. In the year 2023, Alvotech had annual revenue of $93.38M with 9.84% growth.
Revenue (ttm)
$114.39M
Revenue Growth
+14.27%
P/S Ratio
32.38
Revenue / Employee
$111,494
Employees
1,026
Market Cap
3.70B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 93.38M | 8.37M | 9.84% |
| Dec 31, 2022 | 85.02M | 45.33M | 114.23% |
| Dec 31, 2021 | 39.68M | -29.77M | -42.86% |
| Dec 31, 2020 | 69.45M | -13.23M | -16.00% |
| Dec 31, 2019 | 82.68M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Oscar Health | 6.54B |
| Perrigo Company | 4.56B |
| Surgery Partners | 2.79B |
| Alkermes | 1.73B |
| Integer Holdings | 1.63B |
| Axonics | 387.14M |
| Axsome Therapeutics | 251.02M |
| PROCEPT BioRobotics | 156.33M |
ALVO News
- 3 days ago - Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024 - GlobeNewsWire
- 11 days ago - Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update - GlobeNewsWire
- 11 days ago - Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK - GlobeNewsWire
- 12 days ago - Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. - Business Wire
- 12 days ago - Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. - GlobeNewsWire
- 17 days ago - Alvotech S.A. Annual General Meeting to be held June 7, 2024 - GlobeNewsWire
- 19 days ago - Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) - GlobeNewsWire
- 4 weeks ago - Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 - GlobeNewsWire